Fig. 13.1 Mechanisms of acquired resistance to EGFR-TKI 13.2.1 The T790M Secondary Mutation Third-generation EGFR-TKIs such as osimertinib (AZD9291) and CO-1686 have shown promising activity in treatment-resistant EGFR mutation-positive NSCLCs…
Fig. 14.1 (a) Interaction of TCR and antigen only is insufficient to T-cell activation. Co-stimulator signal with CD80/86 and CD28 leads to adequate activation. (b) CTLA-4 has higher affinity than…
Gene Smoking status Histology Genetic alteration ROS1 Primarily never smokers AD ROS1 translocations RET Primarily never smokers AD RET translocations HER2 Primarily never smokers AD HER2 mutations HER2 amplification BRAF…
Fig. 18.1 Therapy-targeted pathways in lung cancer Targeted therapy in lung cancer and the drugs that influence them. EGF, epidermal growth factor; TGF-α, transforming growth factor-α; EGFR, epidermal growth factor…
Release date Title April 2005 Draft preliminary concept paper: Drug-Diagnostic Co-development Concept Paper July 2011 Draft Guidance for Industry and Food and Drug Administration Staff: In Vitro Companion Diagnostic Devices…
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Rash acneiform Papules and/or pustules covering<10 % BSA, which may or may not be associated with symptoms of pruritus or…
Regimen N (%) AE (N) AE (%) Carboplatin + paclitaxel 140 35.4 12 8.6 Carboplatin + etoposide 82 20.7 3 3.7 Cisplatin + etoposide 38 9.6 4 10.5 Vinorelbine 30…
© Springer Science+Business Media Singapore 2017Yuichi Takiguchi (ed.)Molecular Targeted Therapy of Lung Cancer10.1007/978-981-10-2002-5_11 11. ALK Mutant Akihiko Gemma1 (1) Division of Pulmonary Medicine, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan…
Author (study name) Year Radiation (Gy/fractions) Chemotherapy N of patients Overall survival Grade 3–4 pneumonitis (%) Treatment-related death (%) Induction Concurrent Consolidation Median (month) 2y rate (%) Hallqvist A (SATELLITE)…
Target Agent Study phase Result References VEGF-A Bevacizumab II Promising [20] II Promising [21] II Positive for PFS, but no benefit in OS [22] VEGFR-1, VEGFR-2, VEGFR-3 Cediranib II Negative…
